TORASEMIDE IN PREVENTION OF MITRAL REGURGITATION AND CHRONIC HEART FAILURE WORSENING IN POSTINFARCTION PERIOD
Abstract
In the review, the results of scientific research provided, conducted with aim to study influence of ischemic mitral regurgitation (IMR) on the development and progressionof chronic heart failure (CHF). The opportunities considered, of torasemide implementation in prevention of the raise of mitral regurgitation grade, development of desadaptive remodelling of the heart, decrease of its electrical instability that presents itself with various cardiac rhythm disorders, and of prevention ofdevelopment and progression of the CHF. Benefits of torasemide over furosemideare revealed in management of congestive CHF at the background of IMR inpostinfarction patients.
About the Authors
A. A. Abdullaev
Dagestan State Medical University of the Ministry of Health
Russian Federation
Makhachkala
Competing Interests: конфликт интересов не заявляется
Russian Federation
Makhachkala
Competing Interests: конфликт интересов не заявляется
I. B. Ibragimova
Dagestan State Medical University of the Ministry of Health
Russian Federation
Competing Interests: Makhachkala
Russian Federation
Competing Interests: Makhachkala
U. A. Islamova
Dagestan State Medical University of the Ministry of Health
Russian Federation
Makhachkala
Competing Interests:
Russian Federation
Makhachkala
Competing Interests:
конфликт интересов не заявляется
R. M. Gafurova
Dagestan State Medical University of the Ministry of Health
Russian Federation
Makhachkala
Competing Interests:
Russian Federation
Makhachkala
Competing Interests:
конфликт интересов не заявляется
N. N. Baytemirova
Dagestan State Medical University of the Ministry of Health
Russian Federation
Makhachkala
Competing Interests:
Russian Federation
Makhachkala
Competing Interests:
конфликт интересов не заявляется
References
1. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2017; 00: 1-66. DOI: 101093/eurheartj/ehx393.
2. Chernyavskiy AM, Ruzmatov TM, Efendiev VU, et al. Mechanisms of ischemic mitral insufficiency. Serdtse 2015; 14 (2): 85-9. (In Russ.). DOI: 10.18087/rhj.2015.2.1998.
3. Grigioni F, Branzi A. Management of asymptomatic mitral regurgitation. Heart 2010; 96 (23): 1938-45. DOI: 10.1136/hrt.2009.184309.
4. Kwon DH, Kusunose K, Obuchowski NA, et al. Predictors and prognostic impact of progressive ischemic mitral regurgitation in patients with advanced ischemic cardiomyopathy: a multi-modality study. Circ Cardiovasc Imaging 2016; 9: e004577. DOI: 10.1161/CIRCIMAGING.115.004577.
5. Larina VN, Alekhin MN, Bart BYa. The syndrome of mitral regurgitation in patients with chronic heart failure. Cardiologiya 2009; 49 (11): 77-80. (In Russ.).
6. Najm HK, Arifi AA, Omron AS, et al. Moderate ischemic mitral regurgitation: Is there a case for early intervention? J of the Saudi Heart Association 2010; 22: 115-9.
7. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38 (36)-(21): 2739-91. DOI: 101093/eurheartj/ehx391.
8. Silbiger JJ. Anatomy, mechanics, and pathophysiology of the mitral annulus. Am. Heart J. 2012; 164(2): 163-76. DOI: 10.1016/j.ahj.2012.05.014.
9. Lima S, Ferreira A, Andrade MJ, et al. Inferior and inferior-lateral location of left ventricular dyssynergy after myocardial infarction begets ischemic mitral regurgitation. Rev Port Cardiol 2009; 28 (11): 1191-200.
10. Zhelnov VV, Andreeva NV, Shcheglova IM, et al. Mitral valve remodeling in patients with acute myocardial infarction and ischemic mitral regurgitation. Cardiologiya 2010; 50 (11): 12-6. (In Russ.).
11. Milano CA, Daneshmand MA, Rankin JS, et al. Survival prognosis and surgical management of ischemic mitral regurgitation. Ann Thorac Surg 2008; 86: 735-44. DOI: 10.1016/j.athoracsur.2008.05.017.
12. Javier I, Perez L, Carlos J, et al. Mitral regurgitation and non-ST-segment elevation acute myocardial infarction: long-term prognosis. Rev Esp Cardiol. 2009; 62 (11): 1267-75. DOI: 10.1016/S1885-5857(09)73354-7.
13. Meris A, Amigoni M, Verma A, et al. Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. J Am Soc Echocardiogr 2012; 25 (5): 535-42. DOI: 101016/J Echo.2012.01.006.
14. Deja MA, Janusiewicz P, Gruszczyńska K, et al Mechanisms of functional mitral regurgitation in cardiomyopathy secondary to anterior infarction. Eur J of Cardio-thorac Surg 2014; 45 (6): 1089-96. DOI: 10.1093/ejcts/ezt660.
15. Yosefy C, Beeri R, Guerrero JL, et al. Mitral regurgitation after anteroapical myocardial infarction: new mechanistic insights. Circulation 2011; 123 (14): 1529-36. DOI: 101161 / CIRCULATIONAHA110.977843.
16. Kuznetsov VA, Yaroslavskaya EI, Krinochkin DV, et al. Chronic mitral regurgitation in postmyocardial infarction patients: gender differences. Cardiologiya. 2015; 55 (2): 60-4. (In Russ.). DOI: 10.18565/ cardio.2015.2.60-64.
17. Soleimani M, Khazalpour M, Cheng G, et al. Moderate mitral regurgitation accelerates left ventricular remodeling after posterolateral myocardial infarction. Ann Thorac Surg 2011; 92(5): 1614-20. DOI: 10.1016/j.athoracsur.2011.05.117.
18. Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial шnfarction in the community: the emerging role of mitral regurgitation. Circulation 2005; 111 (3): 295-301. DOI: 10.1161/01.CIR.0000151097.30779.04.
19. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-19. DOI: 101016/S0140-6736(07)60242-6.
20. Volpe M. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers? QJM 2012; 105 (1): 11-27. DOI: 101093/qjmed/hcr190.
21. Paul J, John S, Jos F, et al. Modulation of reactive oxygen species and collagen synthesisby angiotensin II in cardiac fibroblasts. The Open Hypertension J 2011; 4: 1-17. DOI: 10.2174 / 1876526201104010001.
22. Dhein S, Seidel T, Salameh A, et al. Remodeling of cardiac passive electrical properties and susceptibility to ventricular and atrial arrhythmias. Frontiers in Physiol 2014; 5: 424. DOI: 10.3389/fphys.2014.00424.
23. Bahouth F, Mutlak D, Furman M, et al. Relationship of functional mitral regurgitation to new-onset atrial fibrillation in acute myocardial infarction. Heart 2010; 96 (9): 683-8. DOI: 10.1136/hrt.2009.183822.
24. Bokeria LA, Klimchuk MY. Mitral regurgitation in patients with atrial fibrillation. Current state of the problem, approaches to diagnosis and complex surgical treatment. Annaly arythmologii 2015; 12 (4): 201-13. (In Russ.) DOI: 1015275/ annaritmol.2015.4.2.
25. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2017; 00: 1-66. DOI: 10.1093/eurheartj/ehx393.
26. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Russ J Cardiol 2017; 1 (141): 7-81. DOI: 10.15829/1560-4071-2017-1-7-81.
27. Diagnostics and treatment of chronic heart failure. National guidelines. Serdechnajz nedostatochnost 2013; 14 (7): 379-472. (In Russ.)
28. Messaoudi S, Azibani F, Delcayre C, et al. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 2012; 350: 266-72. DOI: 101016/j.mce.2011.06.038.
29. Drapkina OM, Emelyanov IM. Fibrosis and atrial fibrillation — mechanisms and treatment. Arterial Hypertension 2013; 19 (6): 487-94. (In Russ.)
30. Weber KT, Sun Y, Bhattacharya SK, et al. Myofibroblast mediated mechanisms of pathological remodeling of the heart. Nat Rev Cardiol 2013; 10 (1): 15-26. DOI: 101038/ nrcardio.2012.158.
31. Zannad F, McMurray JJ, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. New N Engl J Med 2011; 364 (1): 11-21. DOI: 10.1056/NEJMoa1009492.
32. Kurlykina NV, Seredenina EM, Orlova YaA. Modern aspects of the application of loop diuretics in heart failure. Terapevticheskiy arkhiv 2017; 89 (9): 115-9. (In Russ.) DOI: 10.17116/terarkh2017899115-119.
33. Gravez B, Tarjus A, Jimenez-Canino R, et al. The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes. PLOS ONE 2013; 8 (9): 1-8. DOI: 10.1371/journal.pone.0073737
34. Harada K, Izawa H, Nishizawa T, et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol 2009; 53: 468-73. DOI: 10.1097/FJC.0b013e3181a717f7.
35. Kido H, Ohtaki Y Torasemide (LUPRAC): a review of its pharmacological and clinical profile. Nippon Yakurigaku Zasshi 2001; 118 (2): 97-105.
36. Mihailidou AS, Loan Le TY, Mardini M, et al. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009; 54 (6): 1306-12. DOI: 10.1161/HYPERTENSIONAHA.109.136242.
37. Stier CT. Mineralocorticoid receptors in myocardial infarction. Hypertension 2009; 54: 1211-2. DOI: 10.1161/HYPERTENSIONAHA.109.140384.
38. López B, Querejeta R, Gonzalez A, et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009; 53 (2): 236-42. DOI: 10.1161/HYPERTENSIONAHA.108.125278.
39. Ageev FT, Zhubrina ES, Gilyarevskiy SR, et al. Comparative effectiveness and safety of long-term use of torasemide in patlients with compensated heart failure. Influence on myocardial fibrosis markers. Serdechnaya nedostatochnost. 2013; 14 (2): 55-62. (In Russ.) DOI: 10.18087/rhfj.2013.2.1801i.
40. Kobalava JD, Kiyakbaev GK. Ways to optimize diuretics therapy for long-term chronic congestive heart failure is a place torasemide extended release. Cardiologiya 2014; 4: 69-77. (In Russ.) DOI: 10.18565/cardio.2014.4.69-77.
41. Shugushev HH, Gaeva AA. Effect of furosemide and torasemide on heart rate variability and ventricular rhythm disorders in patients with chronic heart failure complicating ishemic heart disease: comparative nonrandomized study. Rational Pharmacotherapy in Cardiology 2010; 6 (4): 513-7. (In Russ.) DOI: 10.20996/1819-6446-2010-6-4-513-517.
42. Evdokimova AG. Features of application of torasemide in the practice of the therapeutist. Spravochnik policlinicheskogo vracha 2017; 4: 26-31. (In Russ.).
43. Zhirov IV, Goryunova TV, Osmolovskaya UF, et al. Prolonged-Release torasemide in patients with chronic heart failure. Effective pharmacotherapy 2014; 25: 18-23. (In Russ.)
44. Dlez J, Coca A, de Teresa E, et al. TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. Expert Rev Cardiovasc Ther 2009; 7 (8): 897-904. DOI: 10.1586/erc.09.74.
45. The TORAFIC Investigators Group. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clin Ther 2011; 33 (9): 1204-13. DOI: 10.1016/j.clinthera.2011.08.006.
46. Mareev VYu, Vygodin VA, Belenkov YuN. Diuretic therapy with effective doses of oral diuretics torasemide (Diuver) and furosemide in the treatment of patients with exacerbation of chronic heart failure (DUEL-CHF). Heart Failure 2011; 1: 3-10. (In Russ.)
47. Irkin OI. Application of loop diuretics: could be the first-line drug torasemide? Zdorovye Ukraini 2013; 5: 61. (In Russ.)
Review
For citations:
Abdullaev A.A., Ibragimova I.B., Islamova U.A., Gafurova R.M., Baytemirova N.N. TORASEMIDE IN PREVENTION OF MITRAL REGURGITATION AND CHRONIC HEART FAILURE WORSENING IN POSTINFARCTION PERIOD. Russian Journal of Cardiology. 2018;(5):97-102. (In Russ.)
Views:
910
Email this article 